Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Up 40.5% in October

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 7,670,000 shares, an increase of 40.5% from the October 15th total of 5,460,000 shares. Based on an average daily volume of 31,930,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 5.6% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on TNXP shares. StockNews.com initiated coverage on Tonix Pharmaceuticals in a research report on Wednesday. They issued a “sell” rating on the stock. Alliance Global Partners boosted their target price on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Trading Down 6.4 %

Shares of TNXP stock traded down $0.01 during trading hours on Friday, hitting $0.13. 10,509,191 shares of the company were exchanged, compared to its average volume of 10,158,421. The firm has a market cap of $17.99 million, a PE ratio of 0.00 and a beta of 2.06. The company has a quick ratio of 0.72, a current ratio of 1.15 and a debt-to-equity ratio of 0.13. Tonix Pharmaceuticals has a 1 year low of $0.12 and a 1 year high of $22.14. The firm has a fifty day moving average of $0.15 and a 200 day moving average of $1.44.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 158.64%. The firm had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Analysts expect that Tonix Pharmaceuticals will post -18 earnings per share for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its holdings in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 335,373 shares of the company’s stock after buying an additional 242,358 shares during the period. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent SEC filing. 82.26% of the stock is owned by hedge funds and other institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.